- VERIFIED ANALYTICAL DATA AVAILABLE
- SECURE INSTITUTIONAL PORTAL
- In-Vitro Laboratory Research Use Only
A comprehensive technical summary of Ipamorelin, a synthetic pentapeptide and selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a), noted for its high specificity and lack of significant ACTH or cortisol stimulation in preclinical models.
Ipamorelin is a synthetic pentapeptide that belongs to the class of Growth Hormone Secretagogues (GHS). It mimics the action of ghrelin, the endogenous “hunger hormone,” by binding to the GHS-R1a receptor in the pituitary gland and hypothalamus.
Unlike earlier generations of GHRPs (such as GHRP-6 or GHRP-2), Ipamorelin is distinguished in research literature by its selectivity. It stimulates the release of growth hormone without significantly affecting the release of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, making it a valuable tool for studying isolated GH physiology.
Ipamorelin functions as a potent agonist at the GHS-R1a, a G-protein coupled receptor. Upon binding:
Crucially, studies (Raun et al., 1998) demonstrate that this stimulation is highly specific, avoiding the “spillover” effects onto ACTH or prolactin secretion pathways observed with non-selective secretagogues.
Given the role of the GH/IGF-1 axis in bone metabolism, Ipamorelin has been studied in rodent models of bone loss and fracture healing. Research indicates that systemic administration in rats can increase bone mineral content (BMC) and bone area. The mechanism likely involves both:
The ghrelin receptor is expressed in pancreatic islets. Research has explored whether Ipamorelin influences insulin secretion.
Some studies suggest it may enhance insulin release from beta cells in a glucose-dependent manner. However, the net effect on glycemic control remains a complex subject of investigation, balancing potential lipolytic effects with insulin sensitivity.
Aagaard et al. (2009) investigated the effects of GH secretagogues on nitrogen balance in surgical patients as a model of catabolic stress.
Findings suggested that while not all markers were significantly altered in the short term, modulation of the GH axis could potentially spare muscle protein breakdown during recovery phases, prompting further research into anti-catabolic applications.
Since Ipamorelin mimics ghrelin, it influences gastric motility.
Rodent studies (Venkova et al., 2009; Greenwood-Van Meerveld et al., 2012) demonstrated that Ipamorelin accelerates gastric emptying and can reverse postoperative ileus.
This effect is mediated via enteric nervous system receptors, suggesting potential utility in research models of gastroparesis or motility disorders.
Unlike ghrelin, which strongly stimulates appetite, Ipamorelin appears to exert a much weaker orexigenic effect in animal models.
Research focuses on understanding why this specific structural analogue potently stimulates the GH axis while activating hypothalamic appetite centers less aggressively than the native ligand.
